Travere Therapeutics, Inc.
TVTX
$33.99
-$1.20-3.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 114.22% | 87.94% | 75.65% | 60.55% | 57.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.22% | 87.94% | 75.65% | 60.55% | 57.08% |
| Cost of Revenue | -1.95% | -5.62% | -7.82% | -12.17% | -10.42% |
| Gross Profit | 1,102.10% | 303.17% | 153.34% | 107.14% | 82.33% |
| SG&A Expenses | 18.13% | 9.13% | 3.38% | -0.54% | -0.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.78% | 2.16% | -2.02% | -6.25% | -5.29% |
| Operating Income | 67.92% | 46.03% | 36.26% | 32.00% | 26.52% |
| Income Before Tax | 74.61% | 55.86% | 45.61% | 14.78% | 6.55% |
| Income Tax Expenses | -101.92% | -127.25% | -109.52% | -46.19% | 19.27% |
| Earnings from Continuing Operations | 74.63% | 55.93% | 45.66% | 14.80% | 6.54% |
| Earnings from Discontinued Operations | 100.16% | -100.02% | -100.32% | -100.35% | -100.87% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.81% | -15.86% | -40.70% | -188.64% | -303.74% |
| EBIT | 67.92% | 46.03% | 36.26% | 32.00% | 26.52% |
| EBITDA | 85.33% | 56.18% | 42.64% | 37.13% | 30.85% |
| EPS Basic | 77.02% | -8.73% | -33.93% | -156.92% | -215.81% |
| Normalized Basic EPS | 70.67% | 49.19% | 37.52% | 34.87% | 33.19% |
| EPS Diluted | 76.74% | -8.73% | -33.93% | -156.92% | -215.81% |
| Normalized Diluted EPS | 69.60% | 49.19% | 37.52% | 34.87% | 33.19% |
| Average Basic Shares Outstanding | 13.19% | 10.01% | 6.81% | 6.25% | 8.50% |
| Average Diluted Shares Outstanding | 17.53% | 10.01% | 6.81% | 6.25% | 8.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |